logo dark logoo light logo
  • Home
  • Company
    • Leadership
    • Board of Directors
  • Therapeutics
    • Rivoceranib
    • Apealea®
    • Expanded Access Program
  • News
    • Press Releases
    • Publications
    • Events
  • Careers
  • Contact Us
Search
logo dark logoo light logo
  • Home
  • Company
    • Leadership
    • Board of Directors
  • Therapeutics
    • Rivoceranib
    • Apealea®
    • Expanded Access Program
  • News
    • Press Releases
    • Publications
    • Events
  • Careers
  • Contact Us
Search
mobile logo
  • Home
  • Company
    • Leadership
    • Board of Directors
  • Therapeutics
    • Rivoceranib
    • Apealea®
    • Expanded Access Program
  • News
    • Press Releases
    • Publications
    • Events
  • Careers
  • Contact Us
Title Image

LSK BioPharma at ASCO 2015

LSK BioPharma at ASCO 2015

May 30, 2015

Dr. Sunil Sharma and Dr. Yoon Koo Kang in front of the Apatinib poster at ASCO 2015.

Read The Abstract

RELATED POSTS

Elevar reports positive Phase II data of adenoid cystic carcinoma therapy
June 7, 2022
Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma
June 6, 2022
Elevar Therapeutics Adds Drs. Honghui Zhou and David Lilienfeld as Vice Presidents
June 2, 2022
Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial
May 26, 2022

Salt Lake City, UT    |    San Francisco, CA    |    Dublin, Ireland    |    Seoul, South Korea

© Copyright 2022 Elevar Therapeutics